

## *Acknowledgement*

**First and foremost I am grateful and thankful to 'God' Allah for allowing me to successfully accomplish this study.**

I wish to thank and to express my gratitude to ***Prof. Dr. Essam El-Din Mohamed Ammar***, Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain-Shams University for his indispensable guidance and suggestions in supervising the work. His constructive encouragement, unforgettable help and tremendous efforts, were behind the accomplishment of this work.

I wish to express my deepest thanks and gratitude ***to Prof. Dr. Abdel-Megeed Ismail Abdel-Megeed*** Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain-Shams University for the valuable time, help, constant support and the great effort he has given to me and for his continuous guidance and encouragement in preparing this study.

Last, I would thank every patient who helped me in this work

**ORAL ANTICOAGULANTS VS. HEPARIN  
IN THE MANAGEMENT OF EARLY  
RECURRENT PREGNANCY LOSS DUE TO  
ANTIPHOSPHOLIPID SYNDROME**

*A thesis*

*Submitted for Partial Fulfillment of the Master Degree in  
Obstetrics and Gynecology*

Presenting By

***Mohammed Ahmed Abu Khalil Mustafa***  
*M. B., B. Ch., (2002) - Al Azhar University*  
*Resident Ob & Gyn, BENHA Teaching Hospital.*

*Under Supervision of*

**Prof. Essam El-Din Mohamed Ammar**

*Professor of Obstetrics and Gynecology*  
*Faculty of Medicine, Ain-Shams University*

**Prof. Abdel-Megeed Ismail Abdel-Megeed**

*Professor of Obstetrics and Gynecology*  
*Faculty of Medicine, Ain-Shams University*

**Faculty of Medicine**  
**Ain Shams University**  
**2009**

مقارنة تأثير مضادات التجلط التي تعطى عن طريق الفم  
بالحبيبات في علاج الإجهاض المبكر المتكرر الناتج عن  
متلازمة مضادات الفوسفوليبيدات

رسالة مقدمة  
توطئة للحصول على  
درجة الماجستير في أمراض النساء و التوليد

المقدمة من الطبيب  
محمد أحمد أبو خليل مصطفى  
بكالوريوس الطب و الجراحة ٢٠٠٢ جامعة الأزهر  
طبيب مقيم توليد و أمراض نساء بمستشفى بنها التعليمي

تحت إشراف  
أ.د./عصام الدين محمد عمار  
أستاذ التوليد وأمراض النساء-كلية الطب – جامعة عين شمس

أ.د./عبد المجيد إسماعيل عبد المجيد  
أستاذ التوليد وأمراض النساء-كلية الطب – جامعة عين شمس

كلية الطب  
جامعة عين شمس  
٢٠٠٩

# II

إقرأ باسم ربك الذى خلق {١} خلق الإنسان  
من علق {٢} إقرأ وربك الأكرم {٣} الذى  
علم بالقلم {٤} علم الإنسان ما لم يعلم {٥}

# ω

سورة العلق الآيات ١ - ٥

# Introduction

## **INTRODUCTION**

---

Habitual abortion or recurrent pregnancy loss (RPL) is the occurrence of repeated pregnancies that end in miscarriage of the fetus, usually before 20 weeks of gestation. RPL affects about 0.34% of women who conceive (*Christiansen et al., 2005*).

Habitual abortion (recurrent pregnancy loss or recurrent miscarriage) is the occurrence of 3 consecutive spontaneous miscarriages (spontaneous abortions). The majority (85%) of women who have had two miscarriages will conceive and carry normally afterwards, so statistically the occurrence of three abortions at 0.34% is regarded as "habitual" (*Moffett et al., 2004*).

There are various causes for habitual abortions, and some are treatable. Some couples never have a cause identified, often after extensive investigations. These causes include the following:

Anatomical conditions, Uterine conditions, Cervical conditions, Chromosomal disorders, Translocations, Aneuploidy, Endocrine disorders, Thrombophilia, Immune factors, Antiphospholipid syndromes, Increased uterine NK cells, Parental HLA sharing, Ovarian factors, Reduced ovarian reserve, Luteal phase defects, Lifestyle factors and Infection (*RCOG. 2002*).

The thrombotic defects associated with fetal wastage are quite common and are due to thrombosis of early placental vessels. Peak fetal loss occurs in the first trimester, but loss also occurs in the second and third trimesters. The thrombotic hemostasis defects associated with recurrent fetal loss include lupus anticoagulants and anticardiolipin antibodies (these 2 comprise the antiphospholipid syndromes associated with recurrent fetal loss), factor XII deficiency, dysfibrinogenemias associated with thrombosis, protein C deficiency, antithrombin deficiency, heparin cofactor II deficiency, and fibrinolytic defects (plasminogen deficiency, tissue plasminogen activator deficiency, and elevated plasminogen activator inhibitor type 1) (*Gris et al.,1993*).

Heparin is used as an injectable anticoagulant. It is also used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machines (*Linhar et al., 1991*). Heparin acts as an anticoagulant, preventing the formation of clots and extension of existing clots within the blood. While heparin does not break down clots that have already formed. It allows the body's natural clot lysis mechanisms to work normally to break down clots that have already formed (*Mulloy et al.,1993*).

In the past decade there has been widespread implementation of oral anticoagulation (warfarin) in preference to antiplatelet treatment (aspirin, indoprofen) (*Whitlon et al.,1978*).

Anticoagulants are given to people to stop thrombosis (blood clotting inappropriately in the blood vessels). This is useful in primary and secondary prevention of deep vein thrombosis, pulmonary embolism, myocardial infarctions and strokes in those who are predisposed (*Austin et al., 1999*).

The most important Oral Anticoagulants are Warfarin (Coumadin), Acenocoumarol, phenprocoumon and Phenindione (*Whitlon et al., 1978*). The oral anticoagulants can be divided into two groups, the 4-hydroxycoumarins and the indandiones. The most common of these include brodifacoum, difenacoum, and chlorphacinone. (*Hoffman et al., 2001*).

Warfarin crosses the placenta and has been associated with an increased incidence of spontaneous abortion, prematurity, and stillbirth. Warfarin embryopathy occurs in 4% to 10% of patients. The risk may be dose-related and appears to be highest if exposure occurs during the 6<sup>th</sup> to 12th weeks of gestation (*Austin et al., 1999*).

Another type of anticoagulant is the direct thrombin inhibitors. Current members of this class include argatroban, lepirudin, and bivalirudin. An oral direct thrombin inhibitor, ximelagatran (Exanta) may replace warfarin for some indications (*Holbrook et al., 2005*).

# Aim of the Work

## **AIM OF THE WORK**

---

- To assess safety and efficiency of oral anticoagulants in treating cases of recurrent miscarriage due to antiphospholipid syndrome.
- To compare pregnancy outcome between heparin and oral anticoagulants groups.

# *Contents*

	<i>Page</i>
- INTRODUCTION.....	1
- AIM OF The WORK.....	4
- REVIEW OF LITERATURE:	
- Recurrent miscarriage .....	5
- RISK FACTORS FOR THROMBOSIS IN 28 PREGNANCY.....	
- THROMBOEMBOLISM IN PREGNANCY: RECURRENCE AND ITS PREVENTION.....	50
- ACQUIRED THROMBOPHILIAS AND PREGNANCY THROMBOPHILIA	73
- ANTICOAGULANTS	101
- ANTICOAGULANTS IN PREGNANCY	114
- PATIENTS AND METHODS.....	129
- RESULTS.....	143
- DISCUSSION.....	154
- SUMMARY .....	163
- CONCLUSION & .....	165
- RECOMMENDATION	166
- REFERENCES.....	167
- ARABIC SUMMARY	

## *List of Tables*

<i>Table No.</i>	<i>Title</i>	<i>Page</i>
1	Differences between mild and sever Preeclampsia .....	
2	Methods to prevent preeclampsia.....	
3	Intrapartum management of pre-eclampsia .....	
4	Descriptive data of the control group.....	
5	Descriptive data of the preeclamptic group.....	
6	Comparison between control group and preeclamptic group of patients as regarding the descriptive data .....	
7	Comparison between control group and preeclamptic group as regarding the degree of albuminuria (cross tab test).....	
8	Comparison between control group and preeclamptic group as regarding the degree of albuminuria (Chi-square test) .....	
9	Comparison between control group and preeclamptic group as regarding serum CRP levels (cross tab test).....	
10	Comparison between control group and preeclamptic group as regarding serum CRP levels (Chi-square test) .....	
11	Correlation matrix between CRP and all studied parameters in the control group .....	
12	Correlation matrix between CRP and all studied parameters in the preeclamptic group.....	

*Continued*

13 Diagnostic validity criteria for evaluation of CRP to discriminate preeclamptic group from control group at each cut of value .....

## *List of Figures*

<i>Fig. No.</i>	<i>Title</i>	<i>Page</i>
1	Crystal structure of C-reactive protein complex with phosphocholine form Biochemistry of myometrial contraction and relaxation. ....	
2	Model of the interaction of CRP with complement.....	
3	Comparison between patient (preeclamptic) and control groups as regarding the CRP titre.....	
4	Diagnostic validity criteria for evaluation of CRP to discriminate preeclamptic group from control group at conc. 6 mg/L .....	
5	ROC curve analysis showing the diagnostic performance of CRP for discriminating pregnancy with pre-eclampsia from those without.....	

## *List of Abbreviations*

ACOG	American College of Obstetricians & Gynecologists
ANP	Atrial Natriuretic Peptide
BMI	Body mass index
CVD	Cerebrovascular disease
DBP	Diastolic blood pressure
DIC	Disseminated intravascular coagulopathy
EFF	Efficacy
EGF	Endothelial growth factor
FP	False positive
GA	gestational age
GH	gestational hypertension
HCG	Human Chorionic Gonadotrophin
HELLP	A syndrome of Haemolysis, Elevated liver enzymes and Low platelet count
HIF	Hypoxia inducible factor
HO	Hemo oxygenase
Ht	Height
IL	Interleukin
IRR	Incidence rate ratio
IUGR	Intrauterine growth restriction
N	Number
P	Probability of error

*Continued*